NCT05678894 (VARIA-CFA) is a NA clinical trial of Scanner and EOS imaging in Femoro-acetabular Impingement, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche.

Who is sponsoring NCT05678894?

NCT05678894 is sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche.

What drugs are being tested in NCT05678894?

Interventions in NCT05678894: Scanner and EOS imaging.

What condition does NCT05678894 study?

NCT05678894 studies Femoro-acetabular Impingement.

Is NCT05678894 still recruiting?

NCT05678894 is currently recruiting now. Last updated 3 December 2025.

Last reviewed 2025-12-03 · How we verify

NCT05678894: VARIA-CFA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-center Comparative Study of Variation in Acetabular Anteversion According to Pelvic Tilt in Patients With Femoro-acetabular Impingement and Healthy Volunteers.

Recruiting now NA Last updated 3 December 2025

What this trial tests

NA trial testing Scanner and EOS imaging in Femoro-acetabular Impingement in 140 participants. Currently enrolling.

Timeline

28 September 2023

Primary endpoint
30 September 2026

30 September 2027

Quick facts

Lead sponsor	GCS Ramsay Santé pour l'Enseignement et la Recherche
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	140
Start date	28 September 2023
Primary completion	30 September 2026
Estimated completion	30 September 2027
Sites	1 location across France

Drugs / interventions tested

Scanner and EOS imaging

Conditions studied

Femoro-acetabular Impingement — all drugs for Femoro-acetabular Impingement →

Sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche — full company profile →

Who can join

Adults 18 to 50, any sex, with Femoro-acetabular Impingement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to show that the upper acetabular anteversions calculated in standing, sitting, sitting hip in maximum flexion and supine positions are lower in patients with symptomatic DWI compared to healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other GCS Ramsay Santé pour l'Enseignement et la Recherche trials

Trials by the same sponsor.

NCT07274657 — Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) · NA · not yet recruiting
NCT07271277 — 3D MRI Assessment of Femoroacetabular Impingement in Patients With ACL Rupture - Exploratory Study · NA · not yet recruiting
NCT07263997 — Assessment of a New Traction Device in Submucosal Dissection of Colorectal Lesions · NA · not yet recruiting
NCT07249645 — Description of Return to Sport in Amateur Athletes Who Underwent Several Functional Tests (K-STARTS, Vertical Jumps and · NA · not yet recruiting
NCT06678646 — Ultrasound-guided Release of the Median Nerve at the Elbow in Patients With Lacertus Syndrome · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05678894 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GCS Ramsay Santé pour l'Enseignement et la Recherche
Last refreshed: 3 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05678894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing